Richard Fisher

Company: Eikonizo Therapeutics

Job title: CSO

Seminars:

Development of EKZ-102, a CNS-Penetrant Small Molecule HDAC6 Inhibitor as a Potential First-in-class DiseaseModifying Therapeutic for ALS 11:00 am

• Eikonizo is developing highly selective, potent, orally bioavailable, CNS-penetrant, first-in-class small molecule HDAC6 inhibitors for neurodegeneration • Development candidate, EKZ-102, is a potentially diseasemodifying therapeutic for both sporadic and familial ALS designed to correct broad proteostasis and intracellular transport defects to protect neurons and preserve function • EKZ-102 IND-enabling studies are underway with planned…Read more

day: Conference Day Two Workshop A